The United States Food and Drug Administration (FDA) has granted accelerated approval to Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, for Balversa intended for the treatment of metastatic bladder cancer, it was reported yesterday.
The product is now indicated in the United States for the treatment of adult patients having locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration called FGFR3 or FGFR2, and whose condition had progressed during or after being previously treated with platinum-containing chemotherapy. Accelerated approval was based on a phase 2 trial that featured 87 patients having locally advanced or metastatic bladder cancer, with FGFR3 or FGFR2 genetic alterations that had advanced after treatment with chemotherapy.
According to the company, continued approval for its drug for the indication is likely to be based on verification and description of clinical benefit in confirmatory trials. The US FDA stated that patients should be selected for treatment with the Janssen drug using a companion diagnostic device that it has approved.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT